A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol
Xiao-Wei Ma
Xiao-Hui Guo
Xin-Hua Xiao
Li-Xin Guo
Xiao-Feng Lv
Quan-Min Li
Yan Gao
Keywords：CilostazolProbucolCombination treatmentAtherosclerosisBiomarkersSynergetic effect
Publication Date：2012-07-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：9( 228-236 )